PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsUS stem cell company given green light for blindness trials

BioNews

US stem cell company given green light for blindness trials

Published 30 January 2013 posted in News and appears in BioNews 643

Author

Ruth Retassie

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).

US company StemCells Inc have received Food and Drug Administration (FDA) authorisation to carry out clinical trials of their treatment for one of the leading causes of blindness in over 55-year-olds...

US company StemCells Inc have received Food and Drug Administration (FDA) authorisation to carry out clinical trials of their treatment for a leading cause of blindness in over 55-year-olds.

This is the latest in a number of clinical trials assessing the potential use of stem cells as a treatment for dry age-related macular degeneration (AMD), which affects around 30 million people worldwide.

StemCells Inc's treatment, which injects purified central nervous system (CNS) stem cells into the patient's retina, has been approved for phase I/II clinical trials to assess its safety and efficacy.

A total of 16 patients will be enrolled in this trial, and they will receive standard ophthalmological examinations throughout the first year. A separate observational study will then assess the patients over the subsequent four years.

There is currently no cure or treatment for dry AMD, although some trials are attempting to delay the vision loss process. It is caused by the degeneration of the cells below the retina in the eye, which causes a loss of photoreceptors and eventually blindness.

Approval was given following positive results in initial tests using a well-established rat model of retinal disease. Study author Dr Raymond Lund said that in this study, published in the European Journal of Neuroscience, 'the effect on vision was long-lasting and correlated with the survival of [stem cells] more than seven months after transplantation'. Furthermore, there was no evidence of any uncontrolled, tumour-like cell growth, an important result in terms of clinical use.

Recently biotech company Advanced Cell Technology and the Jules Stein Eye Institute at the University of California, Los Angeles reported positive results in clinical trials of stem cell injections to treat two different types of eye disease (reported in BioNews 642).

StemCells Inc has already begun clinical trials with purified stem cells in patients paralysed from spinal cord injuries and also for children with Pelizaeus-Merzbacher disease, a rare degenerative disorder of the central nervous system.

Related Articles

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
2 October 2015 • 2 minutes read

UK stem-cell trial for wet AMD goes ahead

by Jenny Sharpe

A potential treatment for wet age-related macular degeneration has been carried out for the first time...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
25 July 2013 • 2 minutes read

Lab-made retina cells functional in mice

by Dr Greg Ball

Light-sensitive cells found in the retina have been grown from mouse embryonic stem cells (ESCs) and successfully transplanted into the eyes of visually impaired mice, restoring some vision...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
28 February 2013 • 1 minute read

First patients receive eye stem cell transplants in attempt to restore sight

by Ana Pallesen

Two patients with corneal blindness have become the first people in the UK to have stem cells transplanted into their eyes in order to restore their sight...

Image by Bill McConkey via the Wellcome Collection. Depicts sperm swimming towards an egg.
CC BY 4.0
Image by Bill McConkey via the Wellcome Collection. Depicts sperm swimming towards an egg.
News
21 February 2013 • 2 minutes read

British lab working with controversial stem cell doctor

by Ana Pallesen

A commercial London laboratory is working with a clinic in Lebanon that uses medical techniques that are not verified by the medical community, and fall outside most countries' legal parameters...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
13 February 2013 • 2 minutes read

Rat's vision restored with stem cell treatment

by Dr Nadeem Shaikh

A potential stem cell therapy for glaucoma — a degenerative eye condition that can lead to blindness — has yielded positive results in animal tests...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
30 January 2013 • 3 minutes read

With an eye to the future - preliminary results of clinical trial in human embryonic stem cell-based therapy of macular degeneration

by Dr Dusko Ilic and 1 others

Last week, Advanced Cell Technology (ACT) of Massachusetts, USA, made two important announcements regarding human embryonic stem (hES) cell-based therapies for the potential treatment of Stargardt's dystrophy and age-related macular degeneration, two devastating degenerative disease leading to blindness....

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
Comment
30 January 2013 • 4 minutes read

Crystal ball gazing: human embryonic stem cells in 2012

by Dr Dusko Ilic

In the last few months of 2011, a couple of stories on human embryonic stem cells hit the headlines. Both were bad news for stem cell researchers...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
30 January 2013 • 2 minutes read

Stem cell transplants hold hope for treating blindness

by Rosemary Paxman

A clinical trial testing the safety of using human embryonic stem cell (hESC) in the treatment of progressive eye conditions has been carried out by researchers in the USA...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
29 November 2012 • 2 minutes read

Britain trials embryonic stem cells as treatment for blindness

by Dr Rachael Panizzo

UK scientists have been granted approval to begin the first clinical trial using embryonic stem cells (ES cells) in Europe, which they hope could lead to an effective treatment for a degenerative eye disease causing blindness...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
15 November 2012 • 1 minute read

Stem cell trial for eye diseases begins

by Dr Sophie Pryor

Doctors in the USA have begun treating patients in two clinical trials for degenerative eye diseases. The studies at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA), will test whether specialised eye cells, which have been produced from human embryonic stem cells (hESCs), can be used to treat dry age-related macular degeneration (dry AMD) and Stargardt's macular dystrophy....

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Artificial testicle research given go-ahead

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

25 July 2022 • 2 minutes read

Women's Health Strategy outlines plans to improve fertility treatment access

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856